Source: StreetInsider

Press Release: Zymeworks : Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for...

Read full article »
Annual Revenue
$25-100M
Employees
250-500
Kenneth Galbraith's photo - Chairman & CEO of Zymeworks

Chairman & CEO

Kenneth Galbraith

CEO Approval Rating

88/100

Read more